Related references
Note: Only part of the references are listed.Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
Stephen S. Whitehead
EXPERT REVIEW OF VACCINES (2016)
The global burden of dengue: an analysis from the Global Burden of Disease Study 2013
Jeffrey D. Stanaway et al.
LANCET INFECTIOUS DISEASES (2016)
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model
Beth D. Kirkpatrick et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Protective and immunological behavior of chimeric yellow fever dengue vaccine
Scott B. Halstead et al.
VACCINE (2016)
A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico
Kristen Bauer et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2015)
Animal models for studying dengue pathogenesis and therapy
Kitti Wing Ki Chan et al.
ANTIVIRAL RESEARCH (2015)
Dengue vaccines: Challenges, development, current status and prospects
A. Ghosh et al.
INDIAN JOURNAL OF MEDICAL MICROBIOLOGY (2015)
Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice
Satoru Watanabe et al.
JOURNAL OF VIROLOGY (2015)
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease
S. R. Hadinegoro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America
Luis Villar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Dengue vaccines at a crossroad
Annelies Wilder-Smith et al.
SCIENCE (2015)
Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers
Guntur Fibriansah et al.
SCIENCE (2015)
Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination
P. Robert Beatty et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity
Naphak Modhiran et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Preclinical and clinical development of a dengue recombinant subunit vaccine
Susan B. Manoff et al.
VACCINE (2015)
Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates
Dhanasekaran Govindarajan et al.
VACCINE (2015)
Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine
Alexander Roberto Precioso et al.
VACCINE (2015)
Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial
Maria Rosario Capeding et al.
LANCET (2014)
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study
Jorge E. Osorio et al.
LANCET INFECTIOUS DISEASES (2014)
被撤回的出版物: Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity (Retracted article. See vol. 112, pg. E2738, 2015)
William B. Messer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Coupling of replication and assembly in flaviviruses
Swapna Apte-Sengupta et al.
CURRENT OPINION IN VIROLOGY (2014)
Progress in the Identification of Dengue Virus Entry/Fusion Inhibitors
Carolina De La Guardia et al.
BIOMED RESEARCH INTERNATIONAL (2014)
T-cell immunity to infection with dengue virus in humans
Daniela Weiskopf et al.
FRONTIERS IN IMMUNOLOGY (2014)
Mouse models to study dengue virus immunology and pathogenesis
Raphael M. Zellweger et al.
FRONTIERS IN IMMUNOLOGY (2014)
A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults
Stephen J. Thomas et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2013)
The global distribution and burden of dengue
Samir Bhatt et al.
NATURE (2013)
Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9-16 Year Olds A Randomized, Controlled, Phase II Trial in Latin America
Luis A. Villar et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2013)
Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies
Shailendra Mani et al.
PLOS ONE (2013)
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells
Daniela Weiskopf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Identifying protective dengue vaccines: Guide to mastering an empirical process
Scott B. Halstead
VACCINE (2013)
Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA
Gustavo H. Dayan et al.
VACCINE (2013)
Current progress in dengue vaccines
Shu-Wen Wan et al.
JOURNAL OF BIOMEDICAL SCIENCE (2013)
Aedes albopictus and the reemergence of Dengue
Giovanni Rezza
BMC PUBLIC HEALTH (2012)
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
Arunee Sabchareon et al.
LANCET (2012)
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
Ruklanthi de Alwis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine
Kevin R. Porter et al.
VACCINE (2012)
A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits
Kanakatte Raviprakash et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus
Oliver J. Brady et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Efficacy of a Tetravalent Chimeric Dengue Vaccine (DENVax) in Cynomolgus Macaques
Jorge E. Osorio et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants
Veerachai Watanaveeradej et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Immune Response to Dengue Virus and Prospects for a Vaccine
Brian R. Murphy et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries
Judit Barniol et al.
BMC INFECTIOUS DISEASES (2011)
Different Innate Signatures Induced in Human Monocyte-derived Dendritic Cells by Wild-Type Dengue 3 Virus, Attenuated but Reactogenic Dengue 3 Vaccine Virus, or Attenuated Nonreactogenic Dengue 1-4 Vaccine Virus Strains
Claire Balas et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines
Rosario Z. Capeding et al.
VACCINE (2011)
Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
Charmagne G. Beckett et al.
VACCINE (2011)
Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity
Federico Narvaez et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection
Ruklanthi de Alwis et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Domain III of the envelope protein as a dengue vaccine target
Maria G. Guzman et al.
EXPERT REVIEW OF VACCINES (2010)
A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes in Flavivirus-Naive Adults
Dennis Morrison et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
Wanwisa Dejnirattisai et al.
SCIENCE (2010)
Development of a recombinant tetravalent dengue virus vaccine: Innmunogenicity and efficacy studies in mice and monkeys
David E. Clements et al.
VACCINE (2010)
Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
Monika Simmons et al.
VIROLOGY (2010)
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults
Wellington Sun et al.
HUMAN VACCINES (2009)
Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2
Ryosuke Suzuki et al.
JOURNAL OF VIROLOGY (2009)
Closing the door on flaviviruses: Entry as a target for antiviral drug design
Rushika Perera et al.
ANTIVIRAL RESEARCH (2008)
Structural proteomics of dengue virus
Rushika Perera et al.
CURRENT OPINION IN MICROBIOLOGY (2008)
A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus
Kanakatte Raviprakash et al.
JOURNAL OF VIROLOGY (2008)
Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus
Samantha Brandler et al.
PLOS NEGLECTED TROPICAL DISEASES (2007)
An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice
Laura J. White et al.
JOURNAL OF VIROLOGY (2007)
Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes
David H. Holman et al.
CLINICAL AND VACCINE IMMUNOLOGY (2007)
Dengue virus type 2:: replication and tropisms in orally infected Aedes aegypti mosquitoes
Ma Isabel Salazar et al.
BMC MICROBIOLOGY (2007)
A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates
L Hermida et al.
VACCINE (2006)
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine:: Phase I clinical trial for safety and immunogenicity
Farshad Guirakhoo et al.
HUMAN VACCINES (2006)
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model
JR Putnak et al.
VACCINE (2005)
Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein
Y Modis et al.
JOURNAL OF VIROLOGY (2005)
Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates
F Guirakhoo et al.
JOURNAL OF VIROLOGY (2004)
Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization
K Jessie et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
A fragment of the envelope protein from dengue-I virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice
L Hermida et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2004)
A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice
L Hermida et al.
JOURNAL OF VIROLOGICAL METHODS (2004)
Dengue viral infections
GN Malavige et al.
POSTGRADUATE MEDICAL JOURNAL (2004)
A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3 ' untranslated region is highly attenuated and immunogenic in monkeys
SS Whitehead et al.
JOURNAL OF VIROLOGY (2003)
Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development
CYH Huang et al.
JOURNAL OF VIROLOGY (2003)
Structure of dengue virus: Implications for flavivirus organization, maturation, and fusion
RJ Kuhn et al.
CELL (2002)
Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine
M Simmons et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2001)
Human skin Langerhans cells are targets of dengue virus infection
SJL Wu et al.
NATURE MEDICINE (2000)
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
F Guirakhoo et al.
JOURNAL OF VIROLOGY (2000)
Live attenuated tetravalent dengue vaccine
N Bhamarapravati et al.
VACCINE (2000)